Cat. No. 1614
Chemical Name: 4-[4-(1,3-benzodioxol-5-yl)-5-(2-py
Biological ActivityPotent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-β-induced proliferation of human osteosarcoma cells. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Inman et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol.Pharmacol. 62 65. PMID: 12065756.
Laping et al (2002) Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol.Pharmacol. 62 58. PMID: 12065755.
Matsuyama et al (2003) SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res. 63 7791. PMID: 14633705.
Watabe et al (2003) TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J.Cell Biol. 163 163. PMID: 14676305.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: SB 431542, supplier, Potent, selective, inhibitors, TGF-βRI, TGF-β, TGF-betaRI, TGFbRI, TGFbR1, tgf-b1, ALK4, ALK7, Transforming, Growth, Factors, Beta, Receptors, Receptor, Serine/Threonine, Kinases, RSTKs, SB431542, stem, cells, GlaxoSmithKline, GSK
Find multiple products by catalog number
New Products in this Area
Potent and selective ALK1 and ALK2 inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.